Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.

Inclusion Criteria: * Subjects with suspected brain tumors undergoing surgical removal as their standard of care will be eligible. These may include subjects status post chemotherapy and/or radiation or subjects who have undergone diagnostic biopsy for their original diagnosis and are felt to be candidates for resection. * Subjects must be eligible for resection as determined by the operating surgeon. * Planned standard of care surgery * Subject age 6 months to 25 years * Life expectancy of more than 12 weeks Exclusion Criteria: * Received an investigational drug within 30 days prior to first dose of Panitumumab IRDye800 * Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment * History of infusion reactions to monoclonal antibody therapies * Pregnant or breastfeeding * Evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in children 1 8 years or 8 to 18 year old males or greater than 460 ms in infants up to 1 year or 8 to 18 year old females) * Magnesium, potassium and calcium \< the lower limit of normal per institution normal lab values * Serum creatinine \> 1.5 times upper reference range * Other lab values that in the opinion of the primary surgeon would prevent surgical resection * Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. * Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis * Subjects not deemed to be appropriate candidates for optimal resection of tumor based on location, involvement of eloquent brain, satellite lesions, or other factors not specifically listed here